RxDoctor Payments Data

Tien Nguyen, MD

Cardiovascular Disease · East Setauket, NYNPI 1861455412

Payments from drug & device makers

$1,169in general payments, 2019–2025

Across 27 payments — averaging $43.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$542
  • Boehringer Ingelheim$265
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$82
  • Cook Medical LLC$72
  • Abiomed$40
  • Biotronik Inc.$35
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$1,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,169 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$265,066
Medicare patients
3,345
Services billed
6,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$168,714
EntrestoSacubitril/Valsartan27$30,205
XareltoRivaroxaban20$23,633
Metoprolol Succinate309$4,037
Atorvastatin Calcium389$3,543
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,994
Nebivolol Hcl17$1,525
Ranolazine ErRanolazine18$1,473
Amlodipine Besylate267$1,445
Rosuvastatin Calcium112$1,410
ClopidogrelClopidogrel Bisulfate109$966
Losartan Potassium134$954
Nifedipine ErNifedipine18$884
Isosorbide Mononitrate ErIsosorbide Mononitrate46$849
Carvedilol81$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$31$30,20527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →